This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Dexfenfluramine

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • dexfenfluramine was previously used as an adjunct to dietary treatment for severe obesity. It is the dextrorotatory stereo isomer of fenfluramine, inhibiting the re-uptake and stimulates the release of 5-HT in the hypothalamus which is involved in appetite and feeding behaviour
  • primary pulmonary hypertension and heart valve disorders are recognised to be associated with the use of anorectic agents
  • dexfenfluramine and fenfluramine were withdrawn in October 1997 because of the evidence associated with development of valvular disorders and pulmonary hypertension

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.